GLP-1 drugs are seen as the next top-selling chronic disease treatment, with the potential to transform care the same way cholesterol-lowering statins did for patients at high risk of heart disease more than 30 years ago. The commercial potential is propelling drugmakers like Novo and Lilly to the top of the US and European markets. Investors are also eyeing Pfizer Inc.’s experimental danuglipron after a mid-stage study yielded positive results.
Everything in Premium Digital
。业内人士推荐whatsapp作为进阶阅读
同样因为村里堵车而高兴的，还有宁蒗恒泰农业投资开发有限公司董事长鲁权代表。这两年，苹果上市期间，村里时不时就会堵车。
Последние новости
Что думаешь? Оцени!